Asia's health breakthroughs clash with rising diabetes and pollution risks

New health studies and innovations have emerged across Asia this month. In India, research highlights dietary risks while a biotech firm secures a key patent for cancer treatment. Meanwhile, Singapore funds disease diagnostics, and an AI tool aims to support healthcare workers in underserved regions.

A recent ICMR-INDIAB study found that high intake of refined carbohydrates—such as white rice and wheat products—along with sugary drinks and fried snacks is driving rising diabetes and obesity rates in India. The findings contrast sharply with national dietary guidelines, which recommend whole grains, pulses, millets, and fresh produce while limiting refined sugars and oils.

At the ASSOCHAM 'Illness to Wellness' conference, experts also pointed to air pollution as a major factor in heart disease. The event stressed the need for stronger public health measures to reduce environmental risks. In biotechnology, Cellogen Therapeutics has secured a patent for India's first Bi-Specific CAR T Cell therapy. This advancement could offer new options for cancer patients. Elsewhere, Qure.ai launched 'AIRA', an AI-powered tool designed to assist healthcare workers in low- and middle-income countries by improving diagnostic accuracy and efficiency. Globally, the WHO reported ongoing disruptions to health systems due to COVID-19, affecting routine care in many nations. To counter such challenges, NUS Medicine in Singapore received a S$2 million grant to enhance infectious disease diagnostics across Asia.

The studies and innovations highlight both risks and solutions in public health. India's dietary trends and air pollution remain critical concerns, while new therapies and AI tools aim to strengthen medical support. Funding for diagnostics in Asia further signals a push to rebuild health systems weakened by the pandemic.